Apceth approved to start trials of mesenchymal stem cells in Gastric Cancer
Apceth GmbH has received approval to conduct a clinical cancer trial with its genetically modified, adult mesenchymal stem cells. This is an entirely new approach for the treatment of advanced types of cancer for which there is currently no effective treatment available. The multicenter, open label trial will recruit patients suffering from advanced adenocarcinomas of the gastrointestinal tract.
This clinical trial will be initiated at the University Hospital Grosshadern in Munich in the next few weeks in collaboration with experts from the National Center of Tumor Diseases (NCT) in Heidelberg and the Karolinska Institute in Stockholm.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins